诺和诺德(NVO)去年大幅加码美国GLP-1药品广告支出

金吾财讯
Jan 29

金吾财讯 | 广告追踪机构MediaRadar的数据显示,2025年前九个月,诺和诺德(NVO)在美国为Wegovy投入约3.16亿美元广告费,为糖尿病药物Ozempic投入约1.69亿美元,合计接近4.87亿美元,支出规模超过礼来同期投入的两倍。分析指出,去年广告支出激增,与GLP-1药物供应状况改善密切相关。这类药物在2024年大部分时间供不应求,诺和诺德当时曾暂停广告投放,并在2025年随着供应增加后重新加大宣传力道。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10